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Introduction: Hepatic veno-occlusive disease (VOD, or
sinusoidal obstruction syndrome) is a potentially fatal
complication of stem cell transplantation (SCT). Severe VOD
(sVOD) is usually characterized by multi-organ failure (MOF)
and >80% mortality. Deﬁbrotide (DF) is approved in the EU
for the treatment of sVOD in SCT. We report the ﬁnal
results of a large, international compassionate use program
(CUP; 1998-2009) in Europe, the US, Asia, and the Middle
East.
Methods: DF was provided on a compassionate basis or via
single patient (pt) emergency-use requests post-SCT or
chemo-/radiotherapy. Eligibility, DF use, safety, and out-
comes were collected with case record forms. In the US, pts
met Baltimore criteria for VOD and had MOF. At other sites,
pts met Seattle or Baltimore, ultrasound, and/or histological
criteria. Initial dosing recommendation was 10 mg/kg/d (4
divided doses/d IV) titrated up to 60 mg/kg/d based on
tolerability/response. Following results of a US Phase 2 study,
the recommended dose was 25 mg/kg/d. Treatment duration
was up to investigators. Data included adverse events (AEs)
and survival at Day+100 post-SCT or start of chemo-/
radiotherapy.
Results: Safety/outcome data were submitted voluntarily for
710 pts receiving 1 DF dose. VOD developed post-SCT in
89% (71% allogeneic; 16% autologous; 2% missing), and post-
chemo-/radiotherapy in 11%. Median age was 25 (range, 0.2-
70) years; 43% were <18 years.
Median days to VOD onset was 13. Symptoms were bili-
rubin >2 mg/dL (88% of patients), weight gain >5% (82%),
hepatomegaly (77%), ascites (67%), right upper quadrant pain
(64%), and MOF (41%). Per Bearman criteria or MOF, 60% had
sVOD.
The median dose was 25 mg/kg/d given for a median of
15d.
AEs were reported in 378 pts (53%; <20% related);
most were serious (364) and fatal (350). Causes of death
were generally reported as AEs; hence the most common
new or worsening AEs were MOF (144, all fatal), VOD
(79, 78 fatal), and sepsis (49, 48 fatal). Serious AEs/fa-
talities were generally similar across doses. Hemorrhage
was reported by 85 pts (55 serious, including 37 fatal),
most commonly gastrointestinal (33) or respiratory (24).
Central nervous system (CNS) hemorrhage was reported
in 10 pts. Respiratory tract hemorrhage was highest in
the 60/80 mg/kg/d dose group (9%) vs lower doses (<5%),
but gastrointestinal and CNS hemorrhages were similar
across doses (6%). Withdrawals due to an AE (63) were
mostly due to hemorrhage (50), primarily gastrointestinal
(22).The Kaplan-Meier (KM) estimate of Day+100 sur-
vival was 54%. The ﬁgure shows KM survival curve by
dose group; in the 25 mg/kg/d group (the approved
EU dose) estimated survival was 58% at Day+100
(Figure 1).
Conclusions: DF was generally well tolerated in this large
CUP; AEs were typical for VOD pts. Consistent with prior
studies, survival was 54% at Day+100. Subgroup analyses
support 25 mg/kg/d as the optimal dose.
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Background: AdV is associated with signiﬁcant morbidity
and mortality. No drug is currently approved for AdV. BCV is
an orally available lipid-conjugate of cidofovir (CDV) that
has demonstrated promise as preemptive therapy in allo
HCT patients (pts) with asymptomatic AdV viremia (VL) in a
Phase 2 study. The pilot portion of a Phase 3 BCV study for
AdV (CMX001-304, AdVise Study; NCT02087306) was
initiated in MAR2014. Preliminary results for 26 subjects
enrolled through 15JUL2014 are described (data cut-off
12SEP2014).
Methods: All subjects receive open-label BCV 100 mg ( 50
kg) or 2 mg/kg (< 50 kg) twice a week.
Results: For the 26 subjects, median age ¼ 6.5 y (range:
0-29), 58% < 12 y; 20 allo HCT pts (16 with disseminated
disease), 4 solid organ transplant pts and 2 chemotherapy
pts; median VL in plasma by quantitative polymerase
chain reaction (PCR) at baseline (BL) 4.8 log10c/mL (range:
undetectable [< 2 log10; < LOD] to > 10 log10) (n ¼ 23);
46% were AdV positive in respiratory secretions, 58% in
